Neurology · District of Columbia
Neurology studies in District of Columbia
42 studies have at least one recruiting site in District of Columbia. Neurology research spans migraine, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke and nerve pain.
42 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersEarly Phase 1
Assistance Delivery and Muscle Coordination
The Catholic University of America
- Location
- Washington D.C., DC
- Eligibility basics
- Ages 20–80
- RecruitingHealthy volunteersEarly Phase 1
Sensory Feedback and Hand Motor Adaptation
The Catholic University of America
- Location
- Washington D.C., DC
- Eligibility basics
- Ages 20–70
- RecruitingPhase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
TG Therapeutics, Inc.
- Location
- Washington D.C., DC + 35 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
argenx
- Location
- Washington D.C., DC + 15 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
argenx
- Location
- Washington D.C., DC + 12 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Washington D.C., DC + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Pfizer
- Location
- Washington D.C., DC + 28 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 42 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Dianthus Therapeutics
- Location
- Washington D.C., DC + 29 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 2
A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)
AllRock Bio, Inc.
- Location
- Washington D.C., DC + 10 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
Celgene
- Location
- Washington D.C., DC + 31 other US sites
- Eligibility basics
- Ages 55–90
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
- Location
- Washington D.C., DC + 23 other US sites
- Eligibility basics
- Ages 60–85
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
- Location
- Washington D.C., DC + 52 other US sites
- Eligibility basics
- Ages 50–85
- RecruitingPhase 2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
- Location
- Washington D.C., DC + 30 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
UCB Biopharma SRL
- Location
- Washington D.C., DC + 41 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.
- Location
- Washington D.C., DC + 27 other US sites
- Eligibility basics
- Ages 55–84
- RecruitingPhase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Pfizer
- Location
- Washington D.C., DC + 10 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Pfizer
- Location
- Washington D.C., DC + 69 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Pfizer
- Location
- Washington D.C., DC + 54 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 39 other US sites
- Eligibility basics
- Ages 21–70
- RecruitingPhase 2/Phase 3
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
Corxel Pharmaceuticals
- Location
- Washington D.C., DC + 19 other US sites
- Eligibility basics
- Ages 18–90
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Washington D.C., DC + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Novartis Pharmaceuticals
- Location
- Washington D.C., DC + 42 other US sites
- Eligibility basics
- Ages 40–70
- RecruitingPhase 1
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
AstraZeneca
- Location
- Washington D.C., DC + 4 other US sites
- Eligibility basics
- Ages 18–60
Who these studies look for
Most require a confirmed diagnosis; memory studies often ask for a study partner who knows you well to attend some visits.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Why do memory studies need a study partner?
A partner can report day-to-day changes the participant may not notice. Each study explains what the partner is asked to do.